Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02577 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Sasikumar Kotagiri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states. Hauptthemen laut MEDLINE: Antineoplastic Agents, DNA Helicases, Nuclear Proteins, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Cancer genomic studies have identified frequent mutations in subunits of the SWI/SNF chromatin remodeling complex, including SMARCA4 in nonsmall cell lung cancer with a frequency of up to 33% in advanced-stage disease, making it the most frequently mutated complex. We and others have identified SMARCA2 to be synthetic lethal to SMARCA4, indicating that SMARCA2 is a high-value therapeutic target. Here, we disclose the discovery and characterization of potent, selective, and orally bioavailable cereblon-based SMARCA2 PROTACs. Biochemically, we showed that YDR1 and YD54 are potent SMARCA2 degraders. Further, we showed the antitumor growth inhibitory activity of YDR1 and YD54 in SMARCA4 mutant xenografts. Finally, we show that YDR1 and YD54 synergize with the KRAS G12C inhibitor sotorasib to inhibit the growth of SMARCA4 and KRAS G12C comutant lung cancer cells. These findings provide evidence for the utility of single agent or combination regimens containing SMARCA2 PROTACs as synthetic lethal therapeutics against SMARCA4 mutant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states.
- Deptartment of Veterinary Medicine & Surgery and Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states.
- Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, United states.
- Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United states.
ORCID-Profile: Yonathan Lissanu
Förderung
- NCI NIH HHS
- National Cancer Institute
- University of Texas MD Anderson Cancer Center
Zitieren
APA
Kotagiri, S., Wang, Y., Han, Y., Liang, X., Blazanin, N., Mazhar, H., Sebastian, M., Nguyen, P. K., Jiang, Y., & Lissanu, Y. (2025). Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02577
Vancouver
Kotagiri S, Wang Y, Han Y, Liang X, Blazanin N, Mazhar H, et al. Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02577
BibTeX
@article{Kotagiri2025,
author = {Kotagiri, Sasikumar and Wang, Yawen and Han, Yanyan and Liang, Xiaobing and Blazanin, Nicholas and Mazhar, Hira and Sebastian, Manu and Nguyen, Phuong Kieu and Jiang, Yongying and Lissanu, Yonathan},
title = {Discovery of Novel, Potent, and Orally Bioavailable SMARCA2 Proteolysis-Targeting Chimeras with Synergistic Antitumor Activity in Combination with Kirsten Rat Sarcoma Viral Oncogene Homologue G12C Inhibitors},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02577}
}
EUVIMED